Prof Meral Beksac (Ankara University Medical School, Ankara, Turkey) and Prof Roman Hájek (University of Ostrava, Ostrava, Czech Republic) discuss results of INTEGRATE study to describe treatment pathways, outcomes and resource use in patients with multiple myeloma in emerging markets.
Initially, Prof Beksac explains the objectives and results of the INTEGRATE study. Prof Hájek then discusses with Prof Beksac the clinical impact and future outcomes of this study. They conclude by discussing the future for multiple myeloma care.
This programme has been supported by an unrestricted educational grant from Takeda